Home > Compound List > Product Information
Sorafenib_Molecular_structure_CAS_284461-73-0)
Click picture or here to close

Sorafenib

Catalog No. DB00398 Name DrugBank
CAS Number 284461-73-0 Website http://www.ualberta.ca/
M. F. C21H16ClF3N4O3 Telephone (780) 492-3111
M. W. 464.8249496 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 281

SYNONYMS

IUPAC name
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
IUPAC Traditional name
sorafenib tosylate
Brand Name
Nexavar
Synonyms
Sorafenib tosylate
sorafenib

DATABASE IDS

PubChem CID 216239
PubChem SID 46505329
CAS Number 284461-73-0

PROPERTIES

Hydrophobicity(logP) 3.8
Solubility Practically insoluble (as tosylate salt)

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.
Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
Indication For the treatment of patients with advanced renal cell carcinoma.
Pharmacology Sorafenib is a multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinases. It is commonly available as a tosylate salt. Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib inhibits tumor growth of the murine renal cell carcinoma, RENCA, and several other human tumor xenografts in athymic mice. A reduction in tumor angiogenesis occurs in some tumor xenograft models.
Toxicity The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals.
Affected Organisms
Humans and other mammals
Biotransformation Sorafenib is metabolized primarily in the liver, undergoing oxidative metabolism, mediated by CYP3A4, as well as glucuronidation mediated by UGT1A9. Sorafenib accounts for approximately 70-85% of the circulating analytes in plasma at steady- state. Eight metabolites of sorafenib have been identified, of which five have been detected in plasma. The main circulating metabolite of sorafenib in plasma, the pyridine N-oxide, shows in vitro potency similar to that of sorafenib. This metabolite comprises approximately 9-16% of circulating analytes at steady-state.
Absorption The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state.
Half Life 25-48 hours
Protein Binding 99.5%
Elimination Following oral administration of a 100 mg dose of a solution formulation of sorafenib, 96% of the dose was recovered within 14 days, with 77% of the dose excreted in feces, and 19% of the dose excreted in urine as glucuronidated metabolites.
External Links
Wikipedia
Drugs.com

REFERENCES